Uneventful Thoracic Healing With Everolimus After Aortic Valve Replacement

• Published in: The Annals of thoracic surgery Vol. 84; no. 1; pp. 271 - 272
• Main Authors: Pascual, Julio, MD, Galeano, Cristina, MD, Celemín, Daniel, MD, Alarcón, Maria C., MD, Marcén, Roberto, MD, Fernández, Ana M., MD, Burgos, Francisco J., MD, Ortuño, Joaquin, MD
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.07.2007; Elsevier Science
• Subjects: Aged; Aortic Valve - surgery; Biological and medical sciences; Cardiothoracic Surgery; Cell Proliferation - drug effects; Everolimus; Humans; Immunosuppressive Agents - adverse effects; Kidney Transplantation; Male; Medical sciences; Signal Transduction - drug effects; Sirolimus - adverse effects; Sirolimus - analogs & derivatives; Surgery; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the heart; Surgery of the respiratory system; Transplantation, Homologous; Wound Healing - drug effects; 5; 35; Respiratory disease; Lactone; Thorax; Heart valve; Macrolide; Treatment; Healing agent; Surgery; Protein synthesis inhibitor; Immunosuppressive agent; Cicatrization; Everolimus; Aortic valve
• ISSN: 0003-4975; 1552-6259
• DOI: 10.1016/j.athoracsur.2007.02.056

Impaired wound healing problems constitute a frequent severe adverse event associated to de novo use of proliferation signal inhibitors sirolimus or everolimus in kidney, heart, and lung transplantation. No published experience on the best practice to manage these drugs in patients scheduled for elective thoracic surgery is available. Herein we present a renal allograft recipient with recurrent cutaneous neoplasia who was maintained on everolimus plus prednisone undergoing aortic valve replacement. Although the most advisable practice may be everolimus withdrawal during the perioperative period, everolimus was maintained with transient dose decrease without any wound healing problem.